Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
March 29, 2018 08:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at Two International Conferences in March
March 09, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present at 30th Annual ROTH Conference
February 28, 2018 16:35 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 06, 2018 09:15 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
December 11, 2017 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
December 05, 2017 08:15 ET
|
Galectin Therapeutics Inc.
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line...
Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
December 04, 2017 16:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing...
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
November 13, 2017 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
November 07, 2017 08:15 ET
|
Galectin Therapeutics Inc.
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...